Clinical trials: Ejection Fraction
Heart Failure With Preserved Ejection Fraction
Isometric Exercise Training in Participants With Heart Failure With Preserved Ejection Fraction
Heart failure with a preserved ejection fraction (HFpEF) is a major cause of morbidity and mortality. Hypertension remains one of the major modifiable risk factors in HFpEF development and progression.
- Trial name
- NCT05551663
- Testing
- Isometric exercise training
- Volunteers
- 48 people
- Sponsor
- St George's, University of London
Heart Diseases, Cardiovascular Diseases
Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany
Heart failure (HF) is a global, public health issue that affects more than 63 million people worldwide; this burden is expected to increase substantially as the population ages.
- Conditions
- Heart Diseases, Cardiovascular Diseases, Heart Failure
- Trial name
- EvolutionHF-DE (NCT06336330)
- Where
- 47 sites in Germany
- Volunteers
- 831 people
- Sponsor
- AstraZeneca
Heart Failure and Reduced Ejection Fraction
Cardiac Left Atrial Evaluation and Response in HFrEF With Sacubitril/Valsartan
Heart failure is an increasingly common condition that can have a significant impact on quality of life and reduce life expectancy. In recent decades, a number of drugs have been developed specifically for this condition.
- Trial name
- CLEAR (NCT07088471)
- Testing
- Sacubtril/Valsartan
- Where
- Ireland
- Volunteers
- 334 people
- Sponsor
- Connolly Hospital Blanchardstown
Cardiorenal Syndrome
Exercise Rehabilitation for Cardiorenal Syndrome in HFrEF Patients
This study aims to investigate the efficacy and safety of exercise rehabilitation in patients with cardiorenal syndrome (CRS). Building on previous research demonstrating that exercise rehabilitation can effectively improve…
- Trial name
- NCT07167368
- Testing
- Standardized Basic Drug Therapy for HFrEF with Chronic Kidney Dysfunction, Home-based Personalized Exercise Rehabilitation
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Haiyan Pan
Heart Failure With Preserved Ejection Fraction
Heart Failure and Preserved Ejection Fraction: Observation of Its Progression and Prognosis (HOPP-BERN)
Analysis of longitudinal data, cardiovascular magnetic resonance (CMR) imaging and health related data, of patients with heart failure and preserved ejection fraction (HFpEF) over a timeframe of 5 years per patient.
- Trial name
- HOPP-BERN (NCT04395846)
- Where
- Switzerland
- Volunteers
- 350 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Heart Failure With Reduced Ejection Fraction, Dilated Cardiomyopathy
v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491
The purpose of this Phase 1b/2a study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MYK-491 in patients with stable heart failure.
- Trial name
- NCT03447990
- Testing
- MYK-491
- Where
- 17 sites in United States, France and 5 more
- Volunteers
- 52 people
- Sponsor
- Bristol-Myers Squibb
Acute Coronary Syndrome, Heart Failure With Reduced Ejection Fraction
Effect of Vericiguat on Acute Coronary Syndrome( ACS）Patients With Ejection Fraction <45%
Investigators evaluate whether differences exsit in acute coronary syndrome（ACS） patients with ejection <45% between participants who take vericiguat regularly and those who donot.
- Trial name
- NCT06321094
- Where
- China
- Volunteers
- 149 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Heart Failure
Pilot Feasibility Study of the Safety and Efficacy of Anakinra in Heart Failure With Preserved Ejection Fraction
This will be a randomized, double-blind, crossover pilot study to measure the safety and feasibility of Interleukin-1 (IL-1) blockade with Anakinra in patients with stable heart failure with preserved ejection fraction.
- Trial name
- NCT01542502
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Virginia Commonwealth University
Cardiac Surgery, Low Ejection Fraction
Impact of Perioperative Levosimendan on Patients Undergoing Cardiac Surgery With Low Ejection Fraction
to compar levosemindan to other cardiac intropic medications that strengthen the heart in diffrent common adult heart surgery with patients with low ejection fraction(weak heart)
- Trial name
- NCT06784570
- Testing
- levosemindan, adrenaline,noreadrenaline,dopamine and doputamine
- Where
- Egypt
- Volunteers
- 240 people
- Sponsor
- Zagazig University
End Stage Cardiac Failure, HFrEF - Heart Failure With Reduced Ejection Fraction
ALP-1 Continuous Intravenous Infusion to Maintain Clinical Stability in Advanced Heart Failure
This is a global multicenter, doubleblind, placebo-controlled, randomized, parallel-group study that compares ALP-1 given in a continuous infusion ( compared to placebo), 250mcg/day on majore outcomes up to 6 months after…
- Conditions
- End Stage Cardiac Failure, HFrEF - Heart Failure With Reduced Ejection Fraction, NYHF Class III-IV
- Trial name
- NCT00610051
- Testing
- Alprostadil
- Where
- Austria
- Volunteers
- 600 people
- Sponsor
- Biopeutics Co., Ltd
Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction
Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials.
- Trial name
- DUP-STEP-HFpEF (NCT06914102)
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 58,387 people
- Sponsor
- Brigham and Women's Hospital
Heart Failure With Reduced Ejection Fraction, Chronic Heart Failure
Emulation of the EMPEROR-Reduced Trial Using Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials.
- Trial name
- NCT07599345
- Testing
- Empagliflozin, Sitagliptin
- Where
- United States
- Volunteers
- 23,955 people
- Sponsor
- Brigham and Women's Hospital
Myocardial Ischemia, Congestive Heart Failure
Stem Cell Study for Patients With Heart Failure
The purpose of this study is to determine if cell therapy with your own cells (autologous cells) delivered with a catheter to regions of the heart with poor blood flow will be safe and if it will improve your ejection fraction…
- Conditions
- Myocardial Ischemia, Congestive Heart Failure, Cardiovascular Disease
- Trial name
- NCT00346177
- Testing
- Autologous Stem Cells
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Losordo, Douglas, M.D.
Heart Failure With Preserved Ejection Fraction, Microvascular Dysfunction
Empagliflozin for Peripheral Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
The goal of this low-intervention clinical trial is to learn about the effect of the drug Empagliflozin in patients with heart failure with preserved ejection fraction.
- Trial name
- NCT06046612
- Testing
- Participants receive 10mg Empaglifozin once daily on prescription from their treating physician. This is not an intervention in this trial, but part of their normal HFpEF treatment
- Where
- Netherlands
- Volunteers
- 48 people
- Sponsor
- Maastricht University Medical Center
Heart Failure, Congestive, Dyspnea
The DIAMOND Study: Distensibility Improvement And Remodeling in Diastolic Heart Failure
The purpose of this study is to test the hypothesis that treatment with oral ALT-711 twice daily for 16 weeks will improve aortic distensibility, exercise tolerance, and quality of life in elderly patients with isolated diastolic…
- Conditions
- Heart Failure, Congestive, Dyspnea, Pulmonary Edema
- Trial name
- NCT00043836
- Testing
- ALT-711
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Synvista Therapeutics, Inc
Heart Failure With Preserved Ejection Fraction (HFPEF)
CAPTURE-HFpEF: National Study of Identification and Phenotyping of Heart Failure With Preserved Ejection Fraction
The goal of this observational study is to improve early detection, characterization, and understanding of heart failure with preserved ejection fraction (HFpEF) in adults at risk of or diagnosed with HFpEF, including men and…
- Trial name
- CAPTURE-HFpEF (NCT07493590)
- Testing
- HFpEF Observational Measurements
- Where
- Denmark
- Volunteers
- 30,000 people
- Sponsor
- Herlev and Gentofte Hospital
Chronic Heart Failure With Reduced Ejection Fraction
Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart Failure
This study will evaluate the efficacy and safety and the best effective dose of QiShen YiQi Dripping Pills in the treatment of chronic heart failure with decreased ejection fraction of CHD (Qi deficiency and blood stasis…
- Trial name
- NCT04983043
- Testing
- Low dose QiShen YiQi Dripping Pills 3 bags, High dose QiShen YiQi Dripping Pills 3 bags
- Where
- 23 sites in China
- Volunteers
- 228 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Effect of Different Types of Aerobic Training on Diastolic Heart Failure Patients
Effect of Different Types of Aerobic Training on Peak VO2 and Ejection Fraction for Diastolic Heart Failure Patients; a Comparative Randomized Control Trial
Background: Heart failure is described by a lack of confirmed efficient therapies and exercise intolerance. Physical activity is related to a lower risk of adverse cardiovascular consequences, involving heart failure.
- Trial name
- NCT05637125
- Testing
- aerobic exercise for upper limb, aerobic exercise for lower limb
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Beni-Suef University
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction
Prospective, randomized, multicenter, open-label clinical trial to evaluate the safety and efficacy of Sacubitril/Valsartan (Sac/Vals) compared to no initiation of the drug in patients with transthyretin cardiac amyloidosis…
- Trial name
- SAVA-TTR (NCT06712030)
- Testing
- Sacubitril / Valsartan
- Where
- Spain
- Volunteers
- 114 people
- Sponsor
- Puerta de Hierro University Hospital
Heart Failure With Preserved Ejection Fraction, Obesity
GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry
GLIDE-HF is a prospective, single-center, non-interventional observational cohort registry conducted within routine outpatient heart failure care at a cardiology clinic in Poland.
- Conditions
- Heart Failure With Preserved Ejection Fraction, Obesity, Diastolic Heart Failure, Pulmonary Hypertension
- Trial name
- GLIDE-HF (NCT07787936)
- Testing
- GLP-1 / GIP receptor agonist
- Where
- Poland
- Volunteers
- 150 people
- Sponsor
- Miedziowe Centrum Zdrowia SA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.